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1. Introduction 
Malignant melanoma of the skin ranks as the number one cause of death from skin cancers. 
Affecting over 125,000 people worldwide and nearly 70,000 persons annually in the United 
States alone (Linos et al., 2009), melanoma incidence has been increasing steadily over the last 
several decades (Erickson and Driscoll, 2010). According to the World Health Organization, 
approximately 20,000 people worldwide die from melanoma each year. One of the most 
striking clinical aspects of melanoma is the profound difference in incidence between persons 
of fair and dark skin complexions (Garbe and Leiter, 2009). Deposition of UV-blocking 
melanin pigment in the epidermis accounts for much of the protection realized by persons of 
dark skin complexion, however risk for melanoma does not simply correlate with amount of 
melanin in the skin. There is now ample evidence that suggests that pheomelanin, the 
red/blonde sulfated melanin pigment expressed in persons of light complexion may promote 
UV-mediated oxidative damage to melanocytes and thus contribute to carcinogenesis (Kvam 
and Tyrrell, 1999; Kadekaro et al., 2006; Abdel-Malek et al., 2008; Smit et al., 2008). In addition, 
as many as a third of melanomas arise from areas of the skin not generally exposed to UV 
light, suggesting that UV-induced mutagenesis only partly accounts for melanoma 
susceptibility. Recent work has shown a link between some of the genes involved in the 
control of pigmentation and other cancer-relevant processes. In particular, we and others are 
interested in the melanocortin 1 receptor (MC1R) signaling pathway in melanocytes which 
determines not only melanoma risk but also the efficiency by which an individual can 
adaptively tan and repair UV-induced photolesions after UV exposure. Data are now 
emerging that link this signaling pathway with the DNA repair pathway responsible for 
clearing UV-induced photodamage from the skin (Kadekaro et al., 2005; Hauser et al., 2006; 
Robinson et al., 2010). In this chapter, we review the link between melanoma and skin 
complexion, focusing on the genes that control innate and adaptive skin pigmentation and the 
mechanisms by which pigmentation differences may account for melanoma risk.  
2. Melanoma - A growing problem 
According to the World Health Organization, about  132,000 people will be diagnosed with 
malignant melanoma of the skin each year. Mainly a disease of fair-skinned individuals, it is 
most prevalent in Western nations in which the majority of the population has descended from 
Northern European ancestry (Tucker, 2009; Rigel, 2010). In the United States, for example, 
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malignant melanoma of the skin currently ranks in the top ten most commonly diagnosed 
cancers of either men or of women. In 2010, for example, it is estimated that 68,130 individuals 
(38,870 men and 29,260 women) were diagnosed with the disease and that it claimed the lives 
of 8,700 people (Croyle, 2011). Melanoma ranks as the second most common cancer in women 
between the ages of 20 and 35, and represents the leading cause of cancer death in women ages 
25 to 30. The melanoma burden is predictably largest in countries with large populations of 
fair skinned individuals living in sunny climates including the United States, Australia, New 
Zealand and Europe (Marks, 2000). Worldwide, Australia reports the highest incidences of 
melanoma (on the order of 40-60 cases per 100,000 individuals) due most likely to their 
geographic proximity to the equator and the high proportion of their population being fair-
skinned immigrants from Europe (Lens and Dawes, 2004).  
Race is the primary risk factor for developing melanoma, with fair-skinned races at greater risk 
than darker-skinned races. For example, fair-skinned Americans are 20 times more likely to 
develop melanoma than their dark-skinned counterparts (Fig. 1). Ultraviolet radiation in the 
form of natural sun exposure and, more recently, artificial UV from tanning salons, is  
also a clear risk factor for melanoma (Linos et al., 2009). The presence of melanin in the skin 
 is thought to explain much of the racial predilection of the disease, with less pigmented 
individuals having skin of a more UV-permeable nature (Veierod et al., 2010). Because  
more UV radiation can penetrate the skin, fair-skinned individuals accrue more cancer- 
causing UV-induced mutations when compared with highly pigmented individuals. 
 
 
Fig. 1. Incidence of Melanoma by Race in the United States of America, 2004-2008. Note that 
the disease is much more prevalent among fair-skinned persons (Croyle, 2011). 
Nonetheless, melanoma can afflict even the darkest individuals, and there are data to suggest 
that the disease tends to be diagnosed at a more advanced stage and is therefore associated 
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with a worse prognosis in such persons (Fleming et al., 1975; Halder and Bridgeman-Shah, 
1995; Bradford, 2009). Despite advances in many areas of cancer detection and treatment, 
melanoma incidence and mortality have been rising for the past several decades (Berwick and 
Wiggins, 2006). The lifetime risk of an American developing melanoma has increased from one 
in 1500 in 1935 to currently about one in 50 (Fig. 2) (Croyle, 2011). According to the American 
Cancer Society (ACS), the incidence rate for melanoma has more than doubled since 1973 
alone, increasing at annual rate on the order of 3-7% (Fig. 3) (American Cancer Society, 2011). 
The reason(s) for this alarming increase remain controversial and are likely multifactorial, 
however, it cannot be argued that melanoma’s increasing incidence and high rate of metastatic 
disease present a legitimate public health problem (Markovic et al., 2007).  
 
 
Fig. 2. U.S. Lifetime melanoma risk, 1935 - 2011 (Lens and Dawes, 2004). 
 
 
Fig. 3. U.S. Melanoma incidence, 1973–2000 (data from the SEER Program of the National 
Cancer Institute), adapted from Lens, et. al. (Lens and Dawes, 2004). 
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3. Risk factors 
Risk factors for melanoma include both inherited and environmental variables (Cho et al., 
2005). Understanding their interaction and relative impact is crucial to optimizing clinical 
practice and public health efforts. 
3.1 Age 
According to the most recent Surveillance Epidemiology and End Results (SEER) data from 
the National Cancer Institute (NCI) based on data collected between 2004-2008, the average 
age at which new patients were diagnosed with melanoma was 60 years (Dennis, 1999; 
Croyle, 2011). In fact, more than half of all new melanoma diagnoses are made in persons 
older than 45 years of age (Fig. 4). It should be noted, however, that melanoma can strike 
persons of any age, and it has been increasingly diagnosed in children and young adults 
(Cust et al., 2011). The reason(s) why melanoma incidence increases with age are not clearly 
understood, but may reflect the typical long latency required for accumulation of sufficient 
mutations caused by environmental factors (in this case UV radiation) to result in 
carcinogenesis (Liu and Soong, 1996).  
 
 
Fig. 4. Age at diagnosis, US Melanoma cases, 2004-2008 (SEER data, NCI). 
3.2 UV radiation    
Though many factors predict melanoma risk (Table 1), UV radiation, in the form of 
ambient sunlight and artificial UV sources such as tanning beds (Lim et al., 2011) is 
among the most important. Strong epidemiologic evidence clearly links UV exposure, 
particularly blistering sunburns early in life, with subsequent melanoma development 
(MacKie and Aitchison, 1982; Gandini et al., 2005). However, in contrast to squamous cell 
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carcinomas (SCC) and basal cell carcinomas (BCC) which are thought to arise from 
keratinocytes rather than melanocytes (Leiter and Garbe, 2008), the mechanism of UV-
mediated carcinogenesis of melanocytes is not well-characterized. In keratinocyte 
malignancies, characteristic “UV-signature” transitional mutations between thymidine 
and cytosine residues are frequently noted in relevant cancer-specific genes such as p53 
(Giglia-Mari and Sarasin, 2003); such changes are not typical in melanoma isolates. 
Nonetheless, most melanomas occur in UV-exposed anatomic locations, and melanoma 
incidence correlates geographically with doseage of ambient UV. It has been suggested 
that the mechanism of UV-mediated carcinogenesis in melanocytes may differ 
fundamentally from that in keratinocytes, possibly mediated by free radicals and 
oxidative species (Autier et al., 2011), however this has not yet been definitively proven. 
Because UV is composed of different subtypes (e.g. UV-A, -B and –C) and each are 
capable of inducing different cellular and DNA damage, the exact wavelengths and 
mechanisms whereby UVR contributes to the development of melanoma are not clear (Seo 
and Fisher, 2010). Different exposure patterns appear to predict different cutaneous 
malignancies (Rass and Reichrath, 2008). Intermittent intense sun exposure such as that 
received by a fair-skinned vacationer in a sunny environment imparts a significant 
increase in risk for developing melanoma (Molho-Pessach and Lotem, 2007) whereas 
chronic sun exposure, typically through occupational or recreational exposure, seems 
more relevant to keratinocyte malignancies (Gandini et al., 2005). In one study, a history 
of sunburn at any age, used as a surrogate for periods of intense exposure, conferred a 
relative risk of melanoma of 2.03 (Tucker, 2009). Serial sunburns across childhood, 
adolescence, and adulthood result in a dose-dependent increase in risk for melanoma 
(Dennis et al., 2008).  
In 1988, 1% of Americans used a tanning bed. By 2007, that number increased to 27% (Fisher 
and James, 2010). There are currently roughly 25,000 indoor tanning facilities in the United 
States alone. The tanning industry represents a multi-billion dollar industry that employs 
more than 150,00 people and that actively seeks to dispel information linking tanning bed 
use with skin cancer risk (Fisher and James, 2010). Nonetheless, the UV energy emitted by 
tanning beds is usually anywhere from two-to ten-fold more intense than direct sunlight, 
and currently there is no mechanistic way to “get a tan” without assuming the mutagenic 
risk of UV radiation and the subsequent risk of malignancy. In fact, the profound rise in 
tanning bed use over the last several years may account for a significant fraction of 
increased melanoma incidence, particularly among young women. Persons who have ever 
used a tanning device have a 50% increased risk of BCC and more than a 100% increased 
risk of SCC (Karagas et al., 2002). Tanning bed use also clearly increases melanoma risk, as 
determined by at a number of separate clinical studies (Walter et al., 1990; Westerdahl et al., 
1994; Chen et al., 1998; Schulman and Fisher, 2009; Lazovich et al., 2010; Mogensen and 
Jemec, 2010). Together, such meta-analyses suggest that regular use of tanning beds triples 
or quadruples the risk of developing melanoma, and that first exposure to indoor tanning 
before 35 years of age raises lifetime risk of melanoma by 75% (Fisher and James, 2010). 
Cutaneous UV injury produces both direct and indirect DNA damage, and each can result 
in accumulation of mutations in skin cells. Direct damage occurs when DNA absorbs UV 
photons, and undergoes cleavage of the 5-6 double bond of pyrimidines. When two 
adjacent pyrimidines undergo this 5-6 double bond opening, a covalent ring structure 
referred to as a cyclobutane pyrimidine dimer (thymine dimer) can be formed. 
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 Age The incidence of melanoma increases dramatically with age. 
 Sun exposure Occupational or recreational UV exposure, living in UV-rich 
geographies (e.g. equatorial locations), living at altitude. 
 Tanning bed use First exposure to indoor tanning before 35 years of age raises 
lifetime risk of melanoma by 75%
 Fair skin complexion 
Deficiency of the highly UV-protective eumelanin epidermal 
pigment allows more UV to penetrate into the skin and 
promote mutagenesis.
 Chronic exposure to 
heavy metals
Chromium, cobalt and other metals may promote oxidative 
mutagenesis in melanocytes. 
 Poor ability to tan A propensity to burn rather than tan after sun exposure 
correlates with increased melanoma risk. 
 History of sunburn One or more severe blistering sunburns as a child or 
teenager increases risk
 Personal history of 
melanoma 
Once a person has been diagnosed with a melanoma, their 
risk for others is heightened. Up to 10% of melanoma 
patients will develop a second melanoma in their lifetime.  
 Family history of 
melanoma 
Inherited CDKN2A defects (the gene that encodes the 
p16INK4A and p14ARF tumor suppressors) are associated 
with familial melanoma
 Having a large 
number of moles 
(nevi) 
Many melanomas appear to arise from pre-existing moles. 
Benign nevi and melanoma both frequently exhibit gain-of-
function mutation in the B-Raf gene.  
 Immune suppression 
Immunosuppressive therapies, for example, as used to 
prevent rejection of solid organs in transplant recipients, are 
associated with melanoma. 
 DNA repair 
deficiency  
Xeroderma pigmentosum (XP) patients who lack one of at 
least eight enzymes in a common  nucleotide excision repair 
(NER) pathway have a 2,000-fold increased risk of skin 
cancers, including melanoma.
Table 1. Melanoma Risk Factors 
Alternatively, a pyrimidine 6-4 pyrimidone (6,4)- photoproduct can result when a 5-6 double 
bond in a pyrimidine opens and reacts with the exocyclic moiety of the adjacent 3' pyrimidine 
to form a covalent 6-4 linkage (Sarasin, 1999). One day’s worth of sun exposure can cause up to 
100,000 potentially mutagenic UV-induced photolesions in each skin cell, and UV radiation 
can also damage cells by free radical formation and oxidative stress (Hoeijmakers, 2009). 
Oxidative DNA lesions are also mutagenic and form after UV-induced free radical attack 
(Meyskens et al., 2001). One particularly well-characterized oxidative lesion is 7,8-dihydro-8-
oxoguanine (8-oxoguanine; 8-OH-dG), which promotes mutagenesis since this guanine 
derivative can pair equally well with cytosine (normal pairing) and adenine (abnormal) and 
consequently cause GC-TA transversion mutations (Schulz et al., 2000). Interestingly, although 
the cutaneous inflammatory response to solar radiation (sunburn) is clearly caused by the UVB 
component of solar radiation, it is the UVA component (which actually represents about 95% 
of ambient sunlight) that penetrates most deeply into the skin. Each has been implicated in 
skin cancer/melanoma formation. UV energy in the UVA range (roughly 315-400 nm) 
promotes mainly oxidative damage to DNA (e.g. 8-oxo-guanine formation) although 
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photodimers can result from UVA exposure as well (Cadet et al., 2005). UVB photons (290-320 
nm) mainly result in thymine dimer formation but can also cause (6,4)-photoproducts and 
oxidative adducts to form. Each of the DNA changes caused by UV radiation is potentially 
mutagenic and actively repaired by cells. Thus, carcinogenesis that results from UV exposure 
(e.g. melanoma) is influenced not only by the amount of environmental UV exposure but also 
by the degree to which damage can be repaired.  
The mechanism of UV-mediated carcinogenesis for keratinocyte malignancies seems to 
correlate with direct UV-induced DNA damage (e.g. cyclobutane dimers) because more than 
half of basal cell and squamous cell carcinomas are found to have signature “UV mutations” in 
cancer-associated genes like p53 (de Gruijl et al., 2001; Cleaver and Crowley, 2002; Bolshakov 
et al., 2003). However, in primary human melanoma samples, such C-T transition mutations 
have not been found with any degree of frequency in known cancer-related genes (Lacour, 
2002; Greenman et al., 2007; Rass and Reichrath, 2008). Thus, although UV exposure is clearly 
linked with melanoma incidence, the actual molecular mechanism of carcinogenesis is unclear. 
Many groups have hypothesized that UV-induced free radicals and subsequent oxidative 
damage may be relevant carcinogenic events in melanocytes (Kvam and Tyrrell, 1997; Runger, 
1999; Larsson et al., 2005; Runger and Kappes, 2008).  
3.3 Heavy metal exposure   
There is growing interest in the contribution of heavy metals (such as chromium and cobalt) to 
melanoma risk. Epidemiologic studies of cohorts exposed either occupationally or through 
joint-replacement (in patients with metal-on-metal hip arthroplasties) to to redox-active heavy 
metals suggest that such exposure may be a risk factor for melanoma (Meyskens and Berwick, 
2008). Through fenton chemistry, heavy metals may contribute independently and in 
conjunction with UV (particularly UVA) to free radical formation in melanocytes; the 
interaction between UV and heavy metals is a field of intensive investigation (Meyskens and 
Yang, 2011). There is also great interest in determining whether heavy metals may influence 
the ability of melanocytes to recover/repair UV-mediated DNA damage (Beyersmann and 
Hartwig, 2008; Joseph, 2009; Whiteside et al., 2010). 
3.4 Large number of moles 
Since many melanomas arise from nevi (moles), it is not suprising that having a large 
number of moles increases an individual’s risk for melanoma (Bataille et al., 1996). It is 
estimated that relative risk for melanoma increases from 1.47 for individuals with 16-40 nevi 
to 6.89 in people with 101-120 nevi (Tucker, 2009). The moles that seem particularly relevant 
to melanoma are dysplastic nevi, which are characterized by histologic atypia (Barnhill and 
Roush, 1990) and may represent a mole in evolution to a less benign state (Hussein, 2005). 
Still, there is a lack of consensus as to whether melanomas grow from existing benign nevi 
or whether nevi and melanomas may share one or more genetic factors. Individuals with 
many nevi are more likely to develop melanomas of the trunk whereas those with lower 
nevus counts require more sun exposure and typically develop cancer in sun-exposed areas 
of the body (Whiteman et al., 2003), suggesting that host factors that drive nevus formation 
may also play a role in carcinogenesis. The role of the BRAF oncogene has been prominently 
emphasized in recent years, and may represent a critical genetic link between nevi and 
melanoma. Gain-of-function signaling mutations in the BRAF gene are found in 60-80% of 
human melanoma isolates (Brose et al., 2002; Davies et al., 2002). Furthermore, about 80% of 
BRAF-mutated melanomas display a common mutation -  the V600E mutation wherein 
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valine is substituted by glutamic acid at position 15- and this very same mutation is found in 
a large number of benign nevi (Pollock et al., 2003; Yazdi et al., 2003). This mutation leads to 
increased signaling through the MAP kinase cascade, and is thought to be a contributing 
factor to melanocyte proliferation.  
3.5 DNA repair  
Nucleotide excision repair (NER) is an evolutionarily-conserved mechanism for repairing 
bulky DNA lesions, including UV-induced photodimers and (6,4)-photoproducts which, if left 
unrepaired, underlie characteristic “UV-signature” pyrimidine transition mutations (de Laat et 
al., 1999; Cleaver et al., 2001). Patients with inherited recessive deficiencies of the NER DNA 
repair pathway are at much heightened risk of developing melanoma and other skin 
malignancies (Leibeling et al., 2006). The NER pathway involves the following basic steps: (1) 
recognition of damage and recruitment of a multiprotein repair complex to the damaged site, 
(2) nicking the damaged strand several nucleotides away on each side of the damaged base(s) 
and excision of the damaged region between the two nicks, 3) filling in the resultant gap by a 
DNA polymerase using the non-damaged strand as a template and (4) ligating the final nick to 
seal the strand. Xeroderma Pigmentosum (XP) is a rare autosomal recessive condition of 
defective NER caused by homozygous loss-of-function in any one of eight or more genes 
central to NER function. XP patients exhibit profound UV hypersensitivity beginning in early 
childhood, and develop epidermal thinning, telangiectasias, lentigenes and patchy hypo- or 
hyper-pigmentation by adolescence(Eugene and Joshi, 2006). Furthermore, despite UV-
avoidance, most XP patients develop actinic keratosis and frank skin malignancies in the first 
decade of life (with a median age of 8 years) (Jen et al., 2009). XP patients have at least a 1,000-
fold increased risk of skin cancers, and have a median age of onset for non-melanomatous skin 
cancer roughly fifty years younger than that of the general population. Similarly, XP patients 
have a markedly higher incidence of cutaneous malignant melanoma, particularly on UV-
exposed skin (Van Patter and Drummond, 1953; Lynch et al., 1967; Jung, 1978), highlighting 
the central relevance of the NER pathway in melanoma prevention. Even though clinical XP 
has been described in the setting of defects in any one of eight genes (XPA, ERCC3 (XPB), XPC, 
ERCC2 (XPD), DDB2 (XPE), ERCC4 (XPF), ERCC5 (XPG), and POLH (XP-V)), mutations in 
XPA or XPC account for at least half of all clinical cases. Though XP is a dramatic phenotype 
that, fortunately, affects only a small fraction of the population, the mechanistic defects 
underlying XP may have relevance to the greater population at risk for sporadic melanoma. 
The contribution of polymorphisms in NER response in the general population’s risk of 
melanoma is an area of active investigation (Li et al., 2006; Millikan et al., 2006; Applebaum et 
al., 2007). 
Resistance to oxidative DNA damage is accomplished on a cellular level by anti-oxidant 
cellular defenses (e.g. glutathione levels) as well as via repair of oxidative lesions by the base 
excision repair (BER) pathway, a highly conserved pathway initiated by one of at least eleven 
damage-specific, monofunctional or bifunctional glycosylases that scan the DNA for specific 
base alterations (Tudek et al., 2006; Russo et al., 2007). After recognition, altered bases are 
cleaved from the  phosphodiesterase backbone by glycolases and repair is achieved via 
involvement of an apurinic intermediate which is cleaved out and then replaced (David et al., 
2007; Hazra et al., 2007; Klungland and Bjelland, 2007). Each of the distinct types of mutagenic 
lesions in the DNA of UV-exposed cells (cyclobutane dimers,(6,4)-photoproducts and 
oxidative lesions such as 8-OH-dG and abasic sites) can promote mutation through aberrant 
repair and/or incorrect base pairing during replication. Much as is the case with NER, 
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variations in the resistance or repair of UV-induced oxidative lesions may be relevant in 
determining mutagenesis in the skin and subsequently risk of melanoma (Phillipson et al., 
2002; Kadekaro et al., 2006; Runger and Kappes, 2008; Song et al., 2009).  
3.6 Personal or family history of skin cancer    
Either because of inherited predisposition or through environmental factors, individuals 
who have had melanoma once have as much as an 8% chance of developing a second 
primary melanoma distinct from their original tumor (Ferrone et al., 2005). Similarly, 
melanoma risk is higher in people with first-degree relatives affected by melanoma (Gandini 
et al., 2005). Melanoma-prone family cohorts have been described with mutations in the  
CDKN2A gene which encodes the p16INK4A and p14ARFtumor suppressors, highlighting 
the importance of the integrity of this pathway in the ability of melanocytes to resist 
malignant degeneration (Hussussian et al., 1994; Kamb et al., 1994; Meyle and Guldberg, 
2009; Hansson, 2010). Perhaps because of increased surveillance, familial melanoma is 
characterized by younger age at diagnosis, thinner lesions, better survival, multiple primary 
lesions, as well as higher incidence of non-melanoma neoplasms (Kopf et al., 1986). 
3.7 Immunodeficiency 
Individuals with defective immunity, particularly T cell immunity, are at increased risk of 
melanoma. Thus, patients with inherited or acquired immune defects, patients on chronic 
immunosuppressive therapies such as cyclosporine, tacrolimus or sirolimus (e.g. following 
solid organ or stem cell transplantation) and cancer patients treated with 
immunosuppressive chemotherapy all have a higher risk of melanoma than their 
immunocompetent counterparts (Otley and Pittelkow, 2000; Calista, 2001; Berg and Otley, 
2002; Reutter et al., 2007). 
3.8 Fair skin complexion and defective tanning response 
Fair-skinned individuals, especially those who fail to tan after sun exposure, have a much 
higher lifetime risk of melanoma than individuals with darker complexions (Rees and Healy, 
1997). Melanoma occurs about twenty times more frequently in fair-skinned individuals than 
in their melanized counterparts (Evans et al., 1988; Franceschi and Cristofolini, 1992). Though 
dark-skinned persons can develop melanoma, the disease is rare in non-white persons and 
tends to occur in less pigmented sites such as the subungual regions, the palms of the hand 
and the soles of the feet (Kabigting et al., 2009). Although the incidence of melanoma in non-
white patients is lower, the mortality rate is higher, perhaps reflecting the disease’s tendency 
to be diagnosed later at a more advanced stage and thus associated with a poorer prognosis 
(Bradford, 2009). Many genes have been described that contribute to skin pigmentation , often 
first identified in animal models with coat color or other pigmentary defects. In our discussion, 
we will focus on one gene in particular- the melanocortin 1 receptor (MC1R)- because its 
function seems particularly relevant to melanoma development. 
4. Skin pigmentation  
4.1 Melanocytes 
Melanocytes are dendritic-type cells derived from the neural crest and are traditionally 
defined by their ability to produce melanin. Comprising 5-10% of total cells in the epidermal 
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basal layer, there are estimated to be between 1,000 and 2,000 melanocytes in every square 
millimeter of human skin (Nordlund, 2007). They are found both in dermal hair follicles 
(where they impart pigment to hair) and in the interfollicular epidermis in the stratum basale 
where they manufacture pigment that accumulates in the outer layers of the epidermis and 
that blocks UV penetration into the deeper layers of the skin. Melanocytes cells are the sole 
manufacturers of melanin in the skin and are thought to be the precursor cell that, upon 
malignant degeneration, develop into melanoma. Via their dendritic projections, melanocytes 
in the stratum basale may be in intimate contact with as many as 30-50 maturing keratinocytes. 
Numerous studies have shown robust contact-dependent as well as paracrine signals between 
melanocytes and keratinocytes. The “epidermal melanin unit” is a term coined to describe the 
close association between one melanocyte and numerous keratinocytes in the epidermis 
(Jimbow et al., 1991). As melanocytes manufacture melanin pigments, they transfer melanin to 
interdigitating keratinocytes where it accumulates in the epidermis (Seiberg, 2001). Melanin 
functions as a “natural sunscreen” to protect the skin against harmful effects of UV radiation 
such as oxidative damage and DNA mutagenesis. The more eumelanin present in the skin, 
both basally and after UV exposure, the more UV-protected and cancer-resistant is the 
individual (Vincensi et al., 1998). Persons with albinism have normal numbers of melanocytes 
in the skin but lack melanin pigments due to loss-of-function of any one of a number of 
pigment biosynthetic enzymes (Oetting, 1999). Because they lack melanin, albinos are much 
more UV sensitive than either fair-skinned pheomelanotic or dark-skinned eumelanotic 
individuals (Oetting, 2000).  
4.2 Melanin pigments 
Skin pigmentation is determined mainly by the type and amount of melanin pigments 
deposited in the epidermis. Melanin is a large bio-polymer composed of subunits of different 
melanotic pigment species formed by sequential oxidation and cyclization of the amino acid 
tyrosine (Riley, 1997) (Fig. 5). Biosynthetic reactions are catalyzed by several pigment enzymes, 
including tyrosinase, the critical rate-limiting enzyme that catalyzes the first two steps in 
melanogenesis (conversion of tyrosine into DOPA and then conversion of DOPA into 
DOPAquinone) (Prota, 1980; Rosei, 2001). Most of the enzymes involved in melanogenesis are 
exclusively found in melanocytes. The final amount and type of melanin produced in the 
melanocyte depends upon both inherited and environmental factors (Hearing, 1999). 
There are two basic types of melanin: eumelanin and pheomelanin. Eumelanin is a brown-
black chemically inert and poorly-soluble pigment polymer that is preferentially expressed 
in persons of darkest complexion. In contrast, because of incorporation of cysteine into the 
molecule, pheomelanin is a more red-yellow sulfur-containing compound (Ito et al., 2000). 
Eumelanin absorbs more UV radiation (is a better “sunscreen”) and is much more 
chemically inert than pheomelanin. The first two reactions of melanin formation are 
common to both eumelanogenesis and pheomelanogenesis; biosynthetic pathways diverge 
after the formation of dopaquinone (Fig. 5). Eumelanins are derived from metabolites of 
dopachrome whereas pheomelanins are produced from sulfhydryl-reduced metabolites 
including cysteinyldopa (Prota, 2000). UV resistance is mainly determined by the absolute 
amount of eumelanin in the skin. Thus, while epidermal pheomelanin levels are fairly 
similar between light-and dark-skinned persons, dark-skinned individuals have much more 
eumelanin in the skin and are therefore much more UV-resistant (Simon and Peles, 2010). 
Besides being a poorer blocker of UV energy, pheomelanin may actually contribute to UV-
induced cellular and DNA damage. UV radiation of pheomelanin is associated with 
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generation of reactive oxidative species (Hubbard-Smith et al., 1992; Hill et al., 1997) and 
photosensitized UV-induced DNA damage when added to melanocytes in vitro (Wenczl et 
al., 1998). Moreover, pheomelanin is much more soluble than eumelanin, even being found 
in the serum and urine of fair-skinned persons(Ito et al., 1983; Ito and Wakamatsu, 1989), 
raising the possibility that UV-exposed pheomelanin (or its metabolites) could leach out of 
melanosomes, diffuse into the nucleus, and interact with DNA to promote mutagenesis 
especially in the context of UV radiation. The contribution of pheomelanin to UV-induced 
carcinogenesis is an ongoing area of investigation. 
 
 
 
Fig. 5. Melanin Biosynthesis. Melanin is a large bioaggregate composed of pigmented 
chemical species synthesized from the amino acid tyrosine. It is present in two major forms: 
(1) the brown/black highly UV-protective “eumelanin” pigment and (2) the red/blonde UV-
permeable “pheomelanin”. Eumelanin and pheomelanin both are synthesized from the 
amino acid tyrosine. Tyrosinase, the enzyme that catalyzes the rate-limiting synthetic 
reaction for either melanin species, is the enzyme that is defective in the most common type 
of albinism. Incorporation of a cysteine into pheomelanin results in the retention of a sulfur 
moiety into the pigment, which may contribute to UV-mediated oxidative injury. The 
melanocyte stimulating hormone (MSH) - melanocortin 1 receptor (MC1R) signaling axis is 
a major determinant of the type and amount of melanin produced by melanocytes in the 
skin.  
4.3 Fitzpatrick scale and UV sensitivity 
Skin color, mainly determined by the amount of eumelanin in the epidermis, correlates well 
with UV resistance. Thus, the darker a person’s skin, the more eumelanin it contains and the 
better that person’s skin is able to withstand acute (e.g. sunburn) and chronic (e.g. cancer) 
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effects of UV. Dermatologists use the “Fitzpatrick Scale”, created in 1975 by a Harvard 
dermatologist named T.B. Fitzpatrick, to describe skin tone (Andreassi et al., 1999). This 
scale is comprised of six categories that define individual phototypes by basal skin color and 
by response to UV radiation (Scherer and Kumar, 2010) (Table 2). Minimal erythematous 
dose, often abbreviated “MED”, is a measure of the skin’s response to ultraviolet radiation 
using erythema (redness, inflammation) as an endpoint. Much more UV radiation is needed 
to “burn” dark skin, and therefore MED is lowest in fair-skinned persons (Lu et al., 1996; 
Andreassi et al., 1999; Kawada, 2000). In most cases, phototypes show a strong correlation 
with MED (Ravnbak, 2010). 
 
Fitzpatrick 
Phototype 
Phenotype 
Epidermal 
eumelanin 
Cutaneous 
response to UV 
MED 
(mJ/cm
2 
)* 
Melanoma 
risk 
I 
Unexposed skin is bright 
white 
Blue/green eyes typical 
Freckling frequent 
Northern European/British 
+/- 
Always burns 
Peels 
Never tans 
15-30 ++++ 
II 
Unexposed skin is white 
Blue, hazel or brown eyes 
Red, blonde or brown hair 
European/Scandinavian  
+ 
Burns easily 
Peels 
Tans minimally 
25-40 +++/++++ 
III 
Unexposed skin is fair 
Brown eyes 
Dark hair 
Southern  or Central 
European  
++ 
Burns 
moderately 
Average tanning 
ability  
30-50 +++ 
IV 
Unexposed skin is light 
brown 
Dark eyes 
Dark hair 
Mediterranean, Asian or 
Latino  
+++ 
Burns minimally
Tans easily  
40-60 ++ 
V 
Unexposed skin is brown 
Dark eyes 
Dark hair 
East Indian, Native 
American, Latino or African 
++++ 
Rarely burns 
Tans easily and 
substantially  
60-90 + 
VI 
Unexposed skin is black 
Dark eyes 
Dark hair 
African or Aboriginal 
ancestry  
++++++ 
Almost never 
burns 
Tans readily and 
profusely  
90-150 +/- 
Minimal erythematous dose (MED) is defined as the least amount of UVB radiation that will result in 
reddening and inflammation of the skin 24h after exposure (i.e. the lowest UV dose that causes a 
sunburn). The more UV sensitive an individual is, the lower the MED of their skin. 
Table 2. Fitzpatrick Scale of Skin Phototypes 
Although innate pigmentation is a major determinant of sun sensitivity, there are other 
genetic and environmental factors that determine how prone to UV damage an individual 
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will be (Rees, 2003). In particular, UV sensitivity correlates well with the degree to which 
epidermal melanin can be up-regulated after UV exposure. Adaptive pigmentation, or 
tanning, is the natural physiologic response of the skin to UV exposure. Adaptive 
pigmentation involves both an increase in the amount of melanin pigment made by 
melanocytes as well as epidermal thickening mediated by proliferation of keratinocytes. 
Both changes serve to increase melanin accumulation in the epidermis so that the skin is 
better protected against subsequent UV exposures. Individuals with defective adaptive 
pigmentation are particularly sun-sensitive and melanoma-prone. Thus, individuals with 
skin phototypes I and II burn easily, have difficulty tanning, and suffer the highest incidence 
of melanoma whereas persons of higher skin phototypes are much more sun-tolerant and 
have much lower incidence of melanoma (Ravnbak, 2010).  
4.4 Genetic determinants of skin color 
Several genes are known to be associated with basal pigmentation in humans and natural 
variation in skin color. Most pigment-determining genes are associated with melanin 
synthesis or melanosome structure/function (Table 3) (Parra, 2007). Others, such as 
microphthalmia (MITF) or Kit ligand (KITLG) control melanocyte migration and 
development (Fleischman et al., 1991; Giebel and Spritz, 1991; Tassabehji et al., 1994}. 
With the exception of tyrosinase, defects in melanin biosynthetic enzymes generally lead 
to dilutional pigmentary effects whereas defects that result in defective melanocyte 
survival or development result in more profound phenotypes such as piebaldism.  
Many pigmentation genes were identified through detailed study of coat color mutations 
in mice and other model organisms (Steingrimsson et al., 2006). Tyrosinase deficiency 
underlies oculocutaneous albinism type I (OCA1) wherein melanocytes are present  
in normal numbers and distribution in the skin but they fail to make any melanin 
pigments at all. As a result, individuals with this severe form of albinism are highly  
UV-sensitive and tend to avoid outdoor activities throughout life. In comparison, 
SLC45A2, also known as MAPT, encodes a membrane-associated transporter protein 
(MATP), which when mutated is responsible for the milder OCA4 form of albinism 
(Newton et al., 2001; Inagaki et al., 2006). Many genes regulate either the ratio or absolute 
levels of eumelanin or pheomelanin expressed in the skin. For example, solute carrier 
family 24 member 5 (SLC24A5), purported to encode a cation exchange protein in 
melanosomes, may account for up to 40% of skin color differences between Europeans 
and Africans (Lamason et al., 2005) and polymorphisms that result in some decrease in 
the activity of TYR, OCA2, MC1R, ASIP and IRF4 have been reported to affect skin color 
in European populations (Sturm, 2009; Edwards et al., 2010; Scherer and Kumar, 2010). 
Thus, it seems that the protein products of several genes together influence basal skin 
pigmentation in humans.  
4.5 Rickets and pigmentation 
It would at first seem highly illogical that fair skin would have been evolutionarily 
selected for over time, as being fair-skinned clearly limits an individual’s ability to 
function in ambient sunlight. However, by considering the native geographical regions 
from which lightly-pigmented persons originated, we might infer why light skin 
complexion may have developed in humans over time. Simply put, fair complexion 
probably evolved so that people living in geographic areas of the world with less intense 
sun exposure (e.g. celtic populations) would have less risk of rickets. Before widespread 
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supplementation of foods with vitamin D, the major source of this essential vitamin was 
the natural sunlight-mediated direct chemical conversion of 7-dehydrocholesterol into 
previtamin D3 that occurs naturally in the epidermis. After synthesis in the skin, 
previtamin D3 then can be modified sequentially by liver and kidney to form the active 
hormone cholecalciferol which is intricately involved in a host of homeostatic 
mechanisms. Deficiency of vitamin D underlies the pathophysiology of rickets, a disease 
state in which altered calcium metabolism leads to a host of severe health consequences, 
including osteomalacia and osteoporosis that lead to delayed growth, chronic pain, 
muscle weakness and disfiguring skeletal abnormalities including bowed legs, scoliosis 
and abnormal bone structure. Since epidermal eumelanin is a potent blocker of UV 
penetration and of the direct chemical conversion of 7-dehydrocholesterol into previtamin 
D3, more UV is needed in dark skin to manufacture sufficient previtamin D3. Therefore, 
as populations moved away from the equatorial regions in which humans evolved to 
more polar climates in which the UV energy of sunlight is much weaker, natural selection 
mechanisms would have favored reduced basal eumelanin in the skin and a lighter skin 
complexion. Moreover, there would have been much less of a need for photoprotection in 
such environments, therefore there would have been no evolutionary pressure to 
maintain a dark phenotype. By gradual lightening of the skin (mediated by reduced 
melanocytic eumelanin production), sufficient UV-mediated vitamin D production in the 
skin would still occur in regions with less ambient sunlight so as to prevent rickets 
(Holick, 1981; Jablonski and Chaplin, 2000). In contrast, in high-UV regions, evolutionary 
pressure would have favored the photoprotection afforded by eumelanin, as evidenced by 
the fact that  populations native to these regions (e.g. Africans, Australian Aborigines, 
Indian subcontinent, etc.) typically having much more epidermal melanin than their 
more-polar counterparts. Thus, it is postulated that the evolution of fair skin may have 
been a positive adaptation due to the requirement of UV-dependent Vitamin D synthesis 
(Jablonski and Chaplin, 2000). 
4.6 The melanocortin 1 receptor (MC1R) and the adaptive tanning response 
There are many genes that control human skin pigmentation (Table 3), but we will focus on 
melanocortin 1 receptor (MC1R), which is a critical locus involved in both pigmentation and 
the tanning response. More relevant to melanoma, pioneering work done by Jonathan Rees 
and colleagues in the mid-90’s showed that loss-of-function polymorphisms of MC1R 
correlated directly with melanoma risk. Studies of the interaction between melanocyte 
stimulating hormone (MSH) and its receptor, the melanocortin 1 receptor (MC1R) have led 
to some understanding of the molecular basis for differences in inherited and adaptive skin 
pigmentation. The MC1R is a seven-transmembrane domain G-protein-coupled receptor 
belonging to the melanocortin receptor subfamily. Ligand-mediated signaling through Mc1r 
involves G-protein activation and resultant increases in levels of intracellular cAMP. 
Production of eumelanin is favored with higher intracellular cAMP concentrations, and 
pheomelanin is preferentially synthesized when cAMP levels are low (Abdel-Malek et al., 
2000). Fairness of skin (and melanoma susceptibility) correlates with polymorphisms of the 
MC1R associated with diminished transmission of MSH signals and a muted cytoplasmic 
cAMP response (Valverde et al., 1995; Rees and Healy, 1997). Genetic support of this 
hypothesis is revealed by studies of the C57BL/6 extension mutant (MC1Re/e) in which 
red/blonde pigmentation occurs as a result of defective MC1R signaling (Robbins et al., 
1993). 
www.intechopen.com
 Skin Pigmentation and Melanoma Risk 
 
53 
Gene  
Pigmentation 
Disorder 
Proposed Function General Structure 
Tyrosinase  (TYR) 
Oculocutaneous 
albinism type 1 
(OCA1) 
Rate-limiting enzyme in 
melanin biosynthesis 
Type I 
transmembrane 
protein 
Tyrosinase-related 
protein-1 (TRP1) 
Oculocutaneous 
albinism type 3 
(OCA3) 
Melanin biosynthesis; 
tyrosinase stabilization 
Type 1 
transmembrane 
protein 
Microphthalmia  
(MITF) 
Waardenburg 
syndrome type 2 
Myc-like master 
transcription factor 
essential for melanocyte 
differentiation and 
survival 
basic-helix-loop-
helix-leucine-zipper 
transcription factor 
Dopachrome 
tautomerase (TRP2) 
Unknown 
Melanin biosynthetic 
enzyme 
Type 1 
transmembrane 
protein 
Solute carrier family 
24 member 5 
(SLC24A5) 
Fair skin 
Melanosomal cation 
exchange 
Membrane 
transporter 
stem cell factor/ kit 
ligand (KITLG) 
Piebaldism 
Transmits survival and 
differentiation signals to 
melanocytes 
Membrane tyrosine 
kinase 
Pmel17  
(gp100; ME20) 
Unknown 
Striation formation; 
melanin polymerization 
Type 1 
transmembrane 
protein 
P/OCA2 
Oculocutaneous 
albinism type 2 
(OCA2) 
Melanosome acidification 
12-transmembrane 
domain-containing 
protein 
OA1 receptor 
Ocular albinism 
(OA) 
Maintenance of 
melanosome size 
G-protein-coupled 
receptor 
Melanocortin 1 
receptor (MC1R) 
Red hair, freckling, 
defective tanning 
Binds to melanocyte 
stimulating hormone and 
generates cAMP signal 
7 transmembrane Gs-
coupled receptor 
Table 3. Partial list of major genes that determine human skin color (Marks and Seabra, 
2001). 
Inability to tan in response to sunlight is a cardinal feature of fair-skinned, UV-sensitive, 
melanoma-prone individuals. Normally, melanocytes respond to UV exposure through 
proliferation and up-regulation of melanin production, the “tanning response”. While it is 
possible that some of this response occurs by direct UV-mediated effects on melanocytes 
themselves, it is likely that the tanning response depends on signals from other cells. In 
particular, the melanocyte stimulating hormone (MSH)- melanocortin 1 receptor (MC1R) 
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signaling axis appears to be central to the adaptive tanning response. MSH, the agonistic 
ligand for MC1R, binds to MC1R on the surface of melanocytes and promotes increases in 
cytoplasmic cAMP. Basal pigmentation likely results in part from this MSH-MC1R 
interaction  from MSH secreted either central from the pituitary gland or from keratinocytes 
in the epidermis. There are three common polymorphisms of the MC1R found in UV-
sensitive and melanoma-prone individuals: Arg151Cys (R151C), Arg160Trp (R160W) and 
Asp294His (D294H). These so-called “red hair color” (RHC) mutations correlate with red 
hair, freckling and tendency to burn rather than tan after UV exposure. Molecularly, the 
RHC MC1R variants display a muted ability to activate adenylate cyclase after MSH 
binding, and thus are associated with a blunted cAMP signaling response. Importantly, 
these loss-of-function polymorphisms of MC1R are also influence susceptibility to 
melanoma and other skin cancers. Thus, persons with defective MC1R signaling have higher 
risk of melanoma than their MC1R-intact counterparts.  
Using a congenic C57Bl/6 mouse model with humanized skin, we showed that Mc1r 
signaling is critical to adaptive pigmentation. Thus, animals with intact Mc1r responded to 
repeated UV exposure by depositing eumelanin in the epidermis, whereas animals that 
were genetically identical except for loss of Mc1r failed to melanize at all in response to the 
same UV exposure (Fig. 6). We also found evidence of a cutaneous MSH-MC1R signaling 
axis in the skin induced by UV and involving MSH production by epidermal keratinocytes. 
Thus we concluded that adaptive pigmentation is dependent on an effective MSH-MC1R 
signaling axis in the skin.  
 
 
Fig. 6. Critical role of the melanocortin 1 receptor in the adaptive tanning response. 
C57Bl/6 mice genetically identical except for being either wild type (Mc1rE/E) or mutant at 
the MSH receptor (Mc1re/e) were treated with the indicated dose of UV. Top-most rows 
show UV-induced ear skin darkening, with corresponding skin sections stained for melanin 
immediately below to show melanin accumulation (black deposits). Note the UV-induced 
skin darkening (black triangles) and melanin accumulation (white triangles) in Mc1rE/E but 
not in Mc1re/e animals (as originally published, D’Orazio, 2006). 
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Fig. 7. The adaptive tanning response. Epidermal keratinocytes receive the brunt of UV 
damage because of their proximity to the surface of the body and because they are the most 
abundant cells in the epidermis. DNA damage in these cells induces activation of the global 
damage response protein p53, which mediates transcriptional activation of the pro-
opiomelanocortin (POMC) gene. The POMC gene encodes a propeptide that is cleaved into 
three protein products: ┚-endorphin, adrenocorticotropic hormone (ACTH) and melanocyte 
stimulating hormone (MSH). MSH is thus produced and secreted from UV-exposed 
keratinocytes, where it is postulated to interact in a paracrine manner with melanocortin 1 
receptors (MC1R) on neighboring melanocytes in the basal epidermis. If MC1R signaling is 
intact, MSH binding induces generation of the second messenger cAMP via activation of 
adenylate cyclase. In melanocytes, elevated cAMP levels trigger a number of downstream 
events including activation of protein kinase A- and subsequent up-regulation of both the 
cAMP responsive binding element (CREB) and microphthalmia (Mitf) transcription factors. 
CREB and Mitf mediate up-regulation of melanin production by induction of tyrosinase and 
other melanin biosynthetic enzymes. Thus, MSH-MC1R signaling leads to enhanced 
pigment synthesis and subsequent transfer of melanin (in the form of melanosomes) to 
epidermal keratinocytes. In this manner, the skin is more protected against subsequent UV 
insults. Recent data suggest that MSH-MC1R signaling may also enhance nucleotide 
excision repair (NER) in melanocytes, which would favor recovery from potentially 
mutagenic UV damage.  
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In subsequent work, David Fisher’s group showed that adaptive pigmention was also 
dependent on p53 function (Cui et al., 2007). Normally thought of in the context as a tumor 
suppressor, p53 is a central DNA damage response mediator that binds to the POMC 
promoter and induces its expression. As a result, UV-exposed keratinocytes  produce and 
secrete ┙-melanocyte stimulating hormone (┙-MSH) which  may then interact with MC1R on 
melanocytes and thereby signal the cells to ramp up production of melanin pigment 
(particularly eumelanin) so that the skin will be more able to cope with subsequent UV insults 
(Fig. 7). The skin’s ability to respond to UV radiation correlates with melanoma risk. Persons 
with loss-of-function polymorphisms of the MC1R fail to respond to MSH signaling and 
demonstrate limited melanization in response to UV exposure. These very people with a 
defective “tanning response” are at very high risk of melanoma; their fair complexion favors 
accumulation of UV-induced mutation by failing to block UV penetration into the skin.  
4.7 MC1R and DNA repair 
We and others are now appreciating that the function of Mc1r in melanocytes clearly 
extends beyond adaptive pigmentation and synthesis of eumelanin. Using genetically 
heterogeneous human melanocytes transfected with Mc1r genes of variable functionality, 
various groups have reported a reproducible link between nucleotide excision repair (NER), 
the pathway responsible for clearing UV-induced thymine dimers and [6,4]-photoproducts 
and Mc1r function and/or cAMP signaling (Bohm et al., 2005; Hauser et al., 2006; Passeron 
et al., 2008; Smith et al., 2008). Using our congenic animal model divergent only at the Mc1r 
locus, we also observe a reproducible difference in the ability to recover from UV damage 
(Fig. 8). Others have also found a correlation between MC1R function and resistance to UV-
mediated oxidative and free radical damage (Song et al., 2009). Determining the molecular 
mechanisms linking MC1R signaling and NER function is an active area of investigation in 
the melanocyte community.  
 
 
Fig. 8. Mc1r function influences repair of UV-induced DNA damage. C57Bl/6 mice 
differing only at the Mc1r locus were irradiated with UV and persistence of thymine dimers 
in the skin was followed over time. Shown are the results of two animals per group. Note 
that animals with intact Mc1r cleared thymine dimers more efficiently.  
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Fig. 9. Pharmacologic induction of melanin in an animal model of the fair-skinned human. 
C57Bl/6 mice harboring a loss-of-function mutation in the melanocortin 1 receptor (Mc1re/e) 
were treated daily with topically-applied control (propylene glycol/ethanol) or with 
forskolin, a drug that directly activates adenylate cyclase and raises cAMP in the skin. 
Photos of shaved mice were taken after 21 days. Note the robust skin darkening (which 
proved to be due to accumulation of eumelanin in the epidermis) in the forskolin-treated 
mice (D'Orazio et al., 2006).  
4.8 Pharmacologic manipulation of MC1R signaling 
Pharmacologic manipulation of melanocytic cAMP levels represents a promising and novel 
approach to alter UV sensitivity and melanoma risk. Pharmacologic MC1R mimetics include 
both small peptides that mimic MSH agonist activity (Abdel-Malek et al., 2009) as well as 
agents that bypass the MC1R to directly manipulate melanocyte cAMP levels. We reported 
that topical application of the adenylate cylase activating drug forskolin restored melanotic 
pigmentation in an animal model of the fair-skinned human (Fig. 10) and that this “sunless 
tanning” was potently protective against UV damage and carcinogenesis of the skin (D'Orazio 
et al., 2006). More recently, Khaled and coworkers showed that a similar UV-protected 
phenotype could be induced not by induction of cAMP generation, but rather by 
pharmacologic interference with clearance of cAMP by topical application of a 
phosphodiesterase inhibitor (Khaled et al., 2010). Small molecule-based approaches of cAMP 
manipulation may offer a critical advantage over MSH peptide mimetics in that fair-skinned, 
UV-sensitive persons most at risk of melanoma are frequently defective in MC1R signaling 
ability, and thus would not be expected to generate a brisk cAMP response upon MSH peptide 
binding. Of course, such agents would be expected to have effects in cells other than 
melanocytes, thus the more  melanocyte-targeted approach of the MSH mimetics may offer 
selective advantages. In any case, rational development of pharmacologic agents capable of 
safely manipulating cAMP levels in epidermal melanocytes might offer UV- and melanoma 
protection by a variety of ways. First, by up-regulating melanin in the skin, fair-skinned 
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individuals would be better protected from UV. Second, sunless tanning by small molecules 
would represent a way to uncouple tanning from UV exposure. Fair-skinned persons seeking 
tans would no longer need to sunbathe or frequent tanning salons to enjoy the cosmetic and 
UV-protective benefits of improved skin pigmentation. Lastly, pharmacomimetics of the 
MC1R pathway hold the promise of enhancing the ability of melanocytes to repair UV-
induced damage and would be expected to result in fewer mutations in UV-exposed skin.  
 
 
Fig. 10. Summary of the influence of pigmentation on melanoma risk. Fair-skinned 
individuals have a much higher risk of melanoma than their dark-skinned counterparts. 
Such individuals are much more UV sensitive, tending to burn rather than tan, after UV 
exposure. Their skin is characterized by much lower levels of epidermal eumelanin and 
consequently much less UV is needed to induce a sunburn (erythema). Furthermore, fair-
skinned persons are more likely to harbor the so-called “red hair color” mutations in their 
melanocortin 1 receptors. These mutations are associated with a blunted MSH signaling 
response and reduced ability to tan. Recent data also suggests that MC1R mutations are 
associated with less efficient nucleotide excision repair. Reduced ability to clear UV-induced 
DNA photolesions would promote mutagenesis after UV exposure. Thus, MC1R-defective 
individuals not only suffer a higher realized dose of UV radiation because their skin has 
insufficient UV-blocking eumelanin but also may accumulate more mutations from UV 
exposure because of defective DNA repair.  
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5. Conclusions 
One of the greatest risk factors for the development of cutaneous melanoma is having a fair 
skin complexion, which is characterized by comparatively low levels of a UV-blocking dark 
pigment called eumelanin in the epidermis. Unlike darker-skinned individuals, persons 
with light complexions suffer much greater skin damage from UV radiation because more 
UV light penetrates through the superficial epidermis to damage both keratinocytes and 
melanocytes in the deeper layers of the epidermis. As a result, fair-skinned individuals are 
exposed to higher “realized” doses of UV radiation in the skin. Thus,  UV-induced 
mutations, which directly contributes to melanoma and other forms of skin cancer, might 
accumulate preferentially in fair-skinned persons over time. We and others are increasingly 
interested in the genetic factors that determine melanoma risk to be able to intervene in the 
carcinogenic process. One of the most important alleles that influences melanoma risk is the 
melanocortin 1 receptor (MC1R), whose function is central to the adaptive pigmentation 
(tanning) response in the skin. This protein mediates signals to melanocytes to induce 
pigment production after UV exposure (the tanning response). Besides regulating adaptive 
pigmentation (tanning), MC1R seems to have a powerful influence on the ability of 
melanocytes to repair UV-induced DNA damage by the nucleotide excision repair pathway. 
Thus, defective MC1R signaling as occurs with the common polymorphisms observed at 
high frequency in melanoma-prone fair-skinned people may predispose to malignancy by 
resulting in inadequate pigment deposition (which would favor UV penetration into the 
skin) and in a sluggish DNA repair response (which would allow UV-induced photodamage 
to promote mutagenesis). These new insights into the many ways in which MC1R function 
protects melanocytes from harmful consequences of UV may help explain why people with 
inherited defects of MC1R signaling suffer a disproportionately high incidence of melanoma 
(Fig. 10). Our long-term goal is to devise rational MC1R-rescue strategies that would reduce 
melanoma risk and UV sensitivity in high-risk, melanoma-prone individuals.  
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